search
Back to results

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

Primary Purpose

Infectious Skin Disease, Bacterial Skin Disease

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
PTK 0796
Linezolid
Sponsored by
Paratek Pharmaceuticals Inc
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infectious Skin Disease focused on measuring CSSSI

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients, ages 18 years to 80 years
  2. Has an acute complicated skin and skin structure infection
  3. Female patients must not be pregnant at the time of enrollment and must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug

Exclusion Criteria:

  1. Has received an investigational drug within past 1 month
  2. Has been previously enrolled in this protocol
  3. Has received >48 hr of a potentially effective systemic antibiotic immediately prior to study drug
  4. Is nursing

Sites / Locations

  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site
  • Paratek Recruiting Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

PTK 0796

Linezolid

Arm Description

Outcomes

Primary Outcome Measures

Number of Participants With Clinical Response in the Modified Intent-to-Treat (mITT) Population
Clinical response is defined as clinical success (CS), which is categorized as a determination by a blinded evaluator (BE) that the infection had sufficiently resolved such that antibiotics were no longer needed, the participant (par.) received ≥1 dose of test article, the par. did not receive non-study antibiotics on >2 calendar days from Day 1 to the Test of Cure assessment, and the par. did not meet any of the criteria for clinical failure. Clinical failure (CF) is categorized as a determination by a BE that the infection had responded inadequately such that alternative antibiotics were needed, the BE discontinued test article due to an adverse event that was possibly/probably related to test article, the primary site of infection was surgically removed, or the par. received potentially effective antibiotics for treatment of the primary infection site on >2 days after study enrollment. A classification of indeterminate is used for any outcome that was not classified as CS or CF.
Number of Participants With Clinical Response in the Clinically Evaluable (CE) Population
Clinical response is defined as CS, which was categorized as a determination by a BE that the infection had sufficiently resolved such that antibiotics were no longer needed, the participant received ≥1 dose of test article, the participant did not receive non-study antibiotics on >2 calendar days from Day 1 to the Test of Cure assessment, and the participant did not meet any of the criteria for clinical failure. CF was categorized as a determination by a BE that the infection had responded inadequately such that alternative antibiotics were needed, the BE discontinued test article due to an adverse event that was possibly/probably related to test article, the primary site of infection was surgically removed, or the participant received potentially effective antibiotics for treatment of the primary infection site on >2 days after study enrollment. A classification of indeterminate is used for any outcome that was not classified as CS or CF.

Secondary Outcome Measures

Number of Participants With Microbiologic Response in the mITT Population
Microbiological response to treatment was determined using the following classification: (a) microbiologic success: all infecting pathogens isolated at Baseline were eradicated or presumed eradicated at the Test of Cure evaluation and no superinfecting pathogen was isolated from the site of infection under study; (b) microbiological failure: persistence or presumed persistence of one or more infecting pathogens or isolation of a superinfecting pathogen from the site of infection under study.
Number of Participants With Microbiologic Response in the Microbiologically Evaluable (ME) Population
Microbiological response to treatment was determined using the following classification: (a) microbiologic success: all infecting pathogens isolated at Baseline were eradicated or presumed eradicated at the Test of Cure evaluation and no superinfecting pathogen was isolated from the site of infection under study; (b) microbiological failure: persistence or presumed persistence of one or more infecting pathogens or isolation of a superinfecting pathogen from the site of infection under study.

Full Information

First Posted
October 17, 2018
Last Updated
September 17, 2020
Sponsor
Paratek Pharmaceuticals Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT03716024
Brief Title
Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
Official Title
A Randomized, Evaluator-Blinded, Phase 2 Study to Compare the Safety and Efficacy of PTK 0796 With Linezolid (Zyvox®) in the Treatment of Adults With Complicated Skin and Skin Structure Infection (cSSSI)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
July 18, 2007 (Actual)
Primary Completion Date
January 7, 2008 (Actual)
Study Completion Date
January 7, 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Paratek Pharmaceuticals Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A Phase II trial to demonstrate the safety and efficacy of PTK 0796 in the treatment of complicated skin and skin structure infections (cSSSI).
Detailed Description
The pharmacologic profile of PTK 0796 in humans suggests that it has the potential to be used safely and effectively for this indication. Data from in vitro and animal studies support this hypothesis. In PTK 0796-CSSI-0702 the safety and efficacy of PTK 0796 in the treatment of cSSSI will be compared to an antibiotic approved for this indication by FDA. Initial treatment will be administered intravenously with the option for subsequent oral treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infectious Skin Disease, Bacterial Skin Disease
Keywords
CSSSI

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
234 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PTK 0796
Arm Type
Experimental
Arm Title
Linezolid
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
PTK 0796
Intervention Description
PTK 0796 100 mg for injection; PTK 0796 capsule 100 mg
Intervention Type
Drug
Intervention Name(s)
Linezolid
Intervention Description
Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
Primary Outcome Measure Information:
Title
Number of Participants With Clinical Response in the Modified Intent-to-Treat (mITT) Population
Description
Clinical response is defined as clinical success (CS), which is categorized as a determination by a blinded evaluator (BE) that the infection had sufficiently resolved such that antibiotics were no longer needed, the participant (par.) received ≥1 dose of test article, the par. did not receive non-study antibiotics on >2 calendar days from Day 1 to the Test of Cure assessment, and the par. did not meet any of the criteria for clinical failure. Clinical failure (CF) is categorized as a determination by a BE that the infection had responded inadequately such that alternative antibiotics were needed, the BE discontinued test article due to an adverse event that was possibly/probably related to test article, the primary site of infection was surgically removed, or the par. received potentially effective antibiotics for treatment of the primary infection site on >2 days after study enrollment. A classification of indeterminate is used for any outcome that was not classified as CS or CF.
Time Frame
10 to 17 days after the last dose of test article (intravenous or oral) (total treatment of up to 14 days)
Title
Number of Participants With Clinical Response in the Clinically Evaluable (CE) Population
Description
Clinical response is defined as CS, which was categorized as a determination by a BE that the infection had sufficiently resolved such that antibiotics were no longer needed, the participant received ≥1 dose of test article, the participant did not receive non-study antibiotics on >2 calendar days from Day 1 to the Test of Cure assessment, and the participant did not meet any of the criteria for clinical failure. CF was categorized as a determination by a BE that the infection had responded inadequately such that alternative antibiotics were needed, the BE discontinued test article due to an adverse event that was possibly/probably related to test article, the primary site of infection was surgically removed, or the participant received potentially effective antibiotics for treatment of the primary infection site on >2 days after study enrollment. A classification of indeterminate is used for any outcome that was not classified as CS or CF.
Time Frame
10 to 17 days after the last dose of test article (intravenous or oral) (total treatment of up to 14 days)
Secondary Outcome Measure Information:
Title
Number of Participants With Microbiologic Response in the mITT Population
Description
Microbiological response to treatment was determined using the following classification: (a) microbiologic success: all infecting pathogens isolated at Baseline were eradicated or presumed eradicated at the Test of Cure evaluation and no superinfecting pathogen was isolated from the site of infection under study; (b) microbiological failure: persistence or presumed persistence of one or more infecting pathogens or isolation of a superinfecting pathogen from the site of infection under study.
Time Frame
10 to 17 days after the last dose of test article (intravenous or oral) (total treatment of up to 14 days)
Title
Number of Participants With Microbiologic Response in the Microbiologically Evaluable (ME) Population
Description
Microbiological response to treatment was determined using the following classification: (a) microbiologic success: all infecting pathogens isolated at Baseline were eradicated or presumed eradicated at the Test of Cure evaluation and no superinfecting pathogen was isolated from the site of infection under study; (b) microbiological failure: persistence or presumed persistence of one or more infecting pathogens or isolation of a superinfecting pathogen from the site of infection under study.
Time Frame
10 to 17 days after the last dose of test article (intravenous or oral) (total treatment of up to 14 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients, ages 18 years to 80 years Has an acute complicated skin and skin structure infection Female patients must not be pregnant at the time of enrollment and must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug Exclusion Criteria: Has received an investigational drug within past 1 month Has been previously enrolled in this protocol Has received >48 hr of a potentially effective systemic antibiotic immediately prior to study drug Is nursing
Facility Information:
Facility Name
Paratek Recruiting Site
City
Anaheim
State/Province
California
ZIP/Postal Code
92804
Country
United States
Facility Name
Paratek Recruiting Site
City
Buena Park
State/Province
California
ZIP/Postal Code
90620
Country
United States
Facility Name
Paratek Recruiting Site
City
Chula Vista
State/Province
California
ZIP/Postal Code
91911
Country
United States
Facility Name
Paratek Recruiting Site
City
Hawaiian Gardens
State/Province
California
ZIP/Postal Code
90716
Country
United States
Facility Name
Paratek Recruiting Site
City
Oceanside
State/Province
California
ZIP/Postal Code
92056
Country
United States
Facility Name
Paratek Recruiting Site
City
San Jose
State/Province
California
ZIP/Postal Code
95124
Country
United States
Facility Name
Paratek Recruiting Site
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46280
Country
United States
Facility Name
Paratek Recruiting Site
City
Butte
State/Province
Montana
ZIP/Postal Code
59701
Country
United States
Facility Name
Paratek Recruiting Site
City
Electra
State/Province
Texas
ZIP/Postal Code
76360
Country
United States
Facility Name
Paratek Recruiting Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77074
Country
United States
Facility Name
Paratek Recruiting Site
City
Wichita Falls
State/Province
Texas
ZIP/Postal Code
76301
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)

We'll reach out to this number within 24 hrs